Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ PRESERVED vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA-approved for acute lymphoblastic leukemia (ALL), meningeal leukemia, non-Hodgkin's lymphoma, mycosis fungoides, psoriatic arthritis, severe psoriasis, breast cancer, head and neck cancers, and rheumatoid arthritis. Off-label uses include ectopic pregnancy, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, and lupus nephritis.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is 3-10 hours for low-dose therapy; at high doses, half-life increases to 8-15 hours due to saturation of renal clearance. Clinical context: Prolonged half-life in renal impairment or third-space fluid accumulation.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized hepatically to polyglutamated methotrexate (active form) via folylpolyglutamate synthetase; also undergoes oxidation via aldehyde oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion), with approximately 5-10% eliminated via biliary/fecal excretion. Enterohepatic recirculation occurs.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 50-60% bound to albumin, with binding saturable at high concentrations.
Approximately 85-90% bound to serum albumin.
Vd is 0.4-0.8 L/kg, indicating distribution into total body water. Higher Vd (1-2 L/kg) in high-dose therapy due to tissue binding and polyglutamation.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 30-90% (dose-dependent, saturable absorption; lower at high doses). IM/Sub Q: 100% (complete absorption). IV: 100%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Contraindicated if creatinine clearance (Cr Cl) <10 m L/min. For Cr Cl 10-30 m L/min: reduce dose by 50%. For Cr Cl 30-60 m L/min: reduce dose by 25%. For Cr Cl >60 m L/min: no adjustment needed. Monitor renal function closely; high methotrexate doses may require additional hydration and alkalinization.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Contraindicated in Child-Pugh class C. For Child-Pugh class B: reduce dose by 50%. For Child-Pugh class A: no dose adjustment. Avoid use in patients with significant liver disease or chronic hepatitis. Monitor liver enzymes.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For acute lymphoblastic leukemia: induction doses of 3.3-5 mg/m² IV or IM, or higher doses per protocol (e.g., 100-1000 mg/m² IV). For juvenile idiopathic arthritis: 10-15 mg/m² once weekly (max 20-25 mg). Doses based on body surface area; adjust for renal function.
Not established; safety and efficacy not determined in pediatric patients.
Elderly patients may have reduced renal function; start at low end of dose range (e.g., 5-7.5 mg weekly for rheumatoid arthritis). Monitor Cr Cl, liver function, and blood counts. Increased risk of myelosuppression and hepatotoxicity. Avoid high-dose methotrexate unless renal function confirmed adequate.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Methotrexate can cause severe toxicity including myelosuppression, hepatotoxicity, nephrotoxicity, pulmonary fibrosis, and severe enterocolitis. Accidental overdose has led to fatalities. It should only be prescribed by physicians experienced with antimetabolite therapy and familiar with its toxicities.
None.
Monitor for bone marrow suppression, hepatotoxicity (liver function tests), renal impairment (serum creatinine), pulmonary toxicity (pneumonia-like symptoms), gastrointestinal toxicity, neurotoxicity (especially in high-dose regimens), and increased risk of infections. Avoid concomitant NSAIDs with high-dose methotrexate. Use with caution in patients with ascites, pleural effusions, or dehydration.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Absolute: hypersensitivity to methotrexate; severe hepatic impairment; severe renal impairment (Cr Cl < 30 m L/min); severe bone marrow suppression; active infection; alcohol use disorder; pregnancy (Category X); breastfeeding. Relative: peptic ulcer disease; ulcerative colitis; obesity; diabetes.
Hypersensitivity to AURLUMYN or any of its components.
Avoid folic acid supplements unless prescribed by your doctor for toxicity management. Caffeine may decrease methotrexate efficacy; limit intake. No specific food restrictions other than maintaining adequate hydration. Avoid grapefruit juice as it may alter methotrexate metabolism.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Contraindicated. Excreted in breast milk; M/P ratio unknown. Potential for infant toxicity.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Increased clearance in pregnancy may require dose escalation; however, contraindicated in pregnancy.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
MEXATE-AQ PRESERVED (methotrexate) is a folate analog antimetabolite. Always verify dosing route: intrathecal use requires preservative-free formulation. Ensure adequate hydration and urine alkalinization (target urine p H >7.0) to prevent methotrexate precipitation in renal tubules. Monitor CBC, LFTs, and creatinine before each dose. Leucovorin rescue is mandatory for high-dose regimens; start 24 hours after methotrexate infusion and continue until methotrexate level <0.1 µmol/L. Avoid concomitant NSAIDs and sulfonamides methotrexate toxicity.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take methotrexate exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol completely due to increased risk of liver damage.,Drink plenty of fluids (at least 2-3 liters per day) to prevent kidney damage.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, mouth ulcers, cough, or shortness of breath immediately.,Use effective contraception during treatment and for at least 3 months after stopping (men and women).,Do not take NSAIDs (e.g., ibuprofen, naproxen) without your doctor's approval; they can increase methotrexate toxicity.,Avoid live vaccines while on treatment.,Store at room temperature, protect from light, and do not freeze.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ PRESERVED vs AURLUMYN, answered by our medical review team.
MEXATE-AQ PRESERVED is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ PRESERVED and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ PRESERVED is: MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ PRESERVED and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ PRESERVED is classified as Category C. Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.